AstraZeneca (pharmaceutical company)āsīlìkāng阿斯利康and / withyǔ与Bristol Myers Squibb (pharmaceutical company)bìzhìtuǒ必治妥reported to be / rumored to bechuánchū传出mergerhébìng合并negotiations / talkstánpàn谈判，potentialqiánzài潜在deal / transactionjiāoyì交易valuationgūzhí估值nearly / approachingjìn近$400 billion USDsìqiān yì měiyuán四千亿美元。
AstraZeneca (pharmaceutical company)
āsīlìkāng
阿斯利康
and / with
yǔ
与
Bristol Myers Squibb (pharmaceutical company)
bìzhìtuǒ
必治妥
reported to be / rumored to be
chuánchū
传出
merger
hébìng
合并
negotiations / talks
tánpàn
谈判
potential
qiánzài
潜在
deal / transaction
jiāoyì
交易
valuation
gūzhí
估值
nearly / approaching
jìn
近
$400 billion USD
sìqiān yì měiyuán
四千亿美元
according to (formal)
jù
据
reports
bàodào
报道
pharmaceutical
zhìyào
制药
giant / major company
jùtóu
巨头
AstraZeneca
āsīlìkāng
阿斯利康
and / with
yǔ
与
Bristol Myers Squibb
bìzhìtuǒ
必治妥
regarding
jiù
就
one / a
yī xiàng
一项
valuation
gūzhí
估值
approximately
yuē
约
$400 billion USD
sìqiān yì měiyuán
四千亿美元
(particle)
de
的
merger
hébìng
合并
to conduct
zhǎnkāi
展开
negotiations
tánpàn
谈判
news / report
xiāoxi
消息
to emerge / to become known
chuánchū
传出
after
hòu
后
AstraZeneca
āsīlìkāng
阿斯利康
share price
gǔjià
股价
to fall / to drop
xiàdiē
下跌
more than / exceeding
yú
逾
7 percent
bǎifēn zhī qī
百分之七
Bristol Myers Squibb
bìzhìtuǒ
必治妥
on the other hand
zé
则
to rise
shàngzhǎng
上涨
more than
yú
逾
5 percent
bǎifēn zhī wǔ
百分之五